Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $140.48, for a total transaction of $421,440.00. Following the completion of the transaction, the insider now owns 141,782 shares of the company's stock, valued at $19,917,535.36. This trade represents a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Solomon Moshkevich also recently made the following trade(s):
- On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04.
- On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00.
- On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $862,689.87.
- On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17.
Natera Stock Performance
NASDAQ:NTRA opened at $138.71 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The firm has a market cap of $18.75 billion, a PE ratio of -78.81 and a beta of 1.80. The business has a 50 day moving average price of $157.48 and a 200-day moving average price of $151.20.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. LRI Investments LLC purchased a new stake in Natera in the 4th quarter worth approximately $29,000. Blue Trust Inc. lifted its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc boosted its holdings in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares during the period. Finally, Principal Securities Inc. raised its holdings in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the company. Piper Sandler lifted their price target on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. The Goldman Sachs Group lifted their target price on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a report on Wednesday, March 19th. Barclays assumed coverage on shares of Natera in a report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 price objective for the company. Finally, Guggenheim raised their price target on Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and an average price target of $178.12.
Read Our Latest Stock Report on NTRA
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
